Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
After finishing at $92.72 in the prior trading day, Astrazeneca plc ADR (NASDAQ: AZN) closed at $90.52, down -2.37%. In other words, the price has decreased by -$2.37 from its previous closing price. On the day, 6.36 million shares were traded. AZN stock price reached its highest trading level at $92.98 during the session, while it also had its lowest trading level at $90.425.
Ratios:
Our goal is to gain a better understanding of AZN by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 34.30 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 21.64. For the most recent quarter (mrq), Quick Ratio is recorded 0.69 and its Current Ratio is at 0.88. In the meantime, Its Debt-to-Equity ratio is 0.71 whereas as Long-Term Debt/Eq ratio is at 0.57.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 12 ’25 when ARADHANA SARIN bought 15,000 shares for $88.88 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AZN now has a Market Capitalization of 280660967424 and an Enterprise Value of 164958519296. As of this moment, Astrazeneca’s Price-to-Earnings (P/E) ratio for their current fiscal year is 30.03, and their Forward P/E ratio for the next fiscal year is 17.52. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.46. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.83 while its Price-to-Book (P/B) ratio in mrq is 6.12. Its current Enterprise Value per Revenue stands at 2.838 whereas that against EBITDA is 8.08.
Stock Price History:
The Beta on a monthly basis for AZN is 0.33, which has changed by 0.3301984 over the last 52 weeks, in comparison to a change of 0.12607694 over the same period for the S&P500. Over the past 52 weeks, AZN has reached a high of $94.01, while it has fallen to a 52-week low of $61.24. The 50-Day Moving Average of the stock is 7.13%, while the 200-Day Moving Average is calculated to be 18.93%.
Shares Statistics:
The stock has traded on average 4.94M shares per day over the past 3-months and 5579780 shares per day over the last 10 days, according to various share statistics. A total of 3.10B shares are outstanding, with a floating share count of 3.10B. Insiders hold about 0.03% of the company’s shares, while institutions hold 16.15% stake in the company. Shares short for AZN as of 1763078400 were 9968173 with a Short Ratio of 2.02, compared to 1760486400 on 6996334. Therefore, it implies a Short% of Shares Outstanding of 9968173 and a Short% of Float of 0.32.
Dividends & Splits
In the trailing 12 months, AZN’s forward annual dividend rate was 3.13, compared to 1.56 this year. Against a Trailing Annual Dividend Yield of 0.03375391. The stock’s 5-year Average Dividend Yield is 2.21. The current Payout Ratio is 66.95% for AZN, which recently paid a dividend on 2025-08-08 with an ex-dividend date of 2025-08-08. Stock splits for the company last occurred on 2015-07-27 when the company split stock in a 2:1 ratio.
Earnings Estimates
Currently, 3.0 analysts are dedicated to thoroughly evaluating and rating the performance of Astrazeneca plc ADR (AZN) in the stock market.The consensus estimate for the next quarter is $1.26, with high estimates of $1.26 and low estimates of $1.26.
Analysts are recommending an EPS of between $4.7 and $4.51 for the fiscal current year, implying an average EPS of $4.59. EPS for the following year is $5.16, with 5.0 analysts recommending between $5.32 and $4.98.
Revenue Estimates
9 analysts predict $15.48B in revenue for. The current quarter. It ranges from a high estimate of $15.9B to a low estimate of $15.18B. As of. The current estimate, Astrazeneca plc ADR’s year-ago sales were $14.89BFor the next quarter, 9 analysts are estimating revenue of $14.39B. There is a high estimate of $14.45B for the next quarter, whereas the lowest estimate is $14.34B.
A total of 22 analysts have provided revenue estimates for AZN’s current fiscal year. The highest revenue estimate was $59.43B, while the lowest revenue estimate was $58.13B, resulting in an average revenue estimate of $58.72B. In the same quarter a year ago, actual revenue was $54.07BBased on 22 analysts’ estimates, the company’s revenue will be $62.44B in the next fiscal year. The high estimate is $65.29B and the low estimate is $60.26B.
